New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 2, 2014
05:23 EDTBSXBoston Scientific reports favorable results in MADIT-CRT study
Boston Scientific reported favorable results in studies related to cardiac resynchronization therapy, or CRT, platinum chromium stent platforms and transcatheter aortic valve replacement, or TAVR. Boston Scientific announced significant findings from the continued analysis of the landmark MADIT-CRT study, demonstrating a significant and sustained survival benefit in the indicated population. The long-term results demonstrated a 41% relative reduction in the risk of death in patients who received a Boston Scientific defibrillator with CRT compared to patients who received a defibrillator alone. In addition to the mortality benefit, the results demonstrate that these patients experienced a 62% relative reduction in the risk of experiencing a first heart failure event when compared to patients who didn't receive CRT therapy. Boston Scientific released new data that continue to reinforce the advantages of platinum chromium stents. The trial compared the safety and effectiveness of the Boston Scientific Platinum Chromium Everolimus-Eluting Stent System, or PtCr EES, to the Abbott Laboratories Cobalt Chromium Everolimus-Eluting Stent System, or CoCr EES. The results show low event rates out to four years with PtCr EES confirming excellent long-term performance. At four years, the PtCr EES also continued to demonstrate advantages over the CoCr EES. The Boston Scientific Lotus Valve System advanced TAVR technology continued to demonstrate impressive performance at three months.
News For BSX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 24, 2015
16:06 EDTBSXBoston Scientific announces first commercial procedures with Watchman Device
This week, three patients in the U.S. received the first implants of the Boston Scientific Watchman Left Atrial Appendage Closure, or LAAC, Device. The WATCHMAN Device offers a novel stroke risk reduction option for high-risk patients with non-valvular atrial fibrillation, or AF, who are seeking an alternative to long-term warfarin therapy. The Watchman Device received FDA approval on Friday, March 13. The first Watchman Device procedures in the U.S. were performed by Shephal K. Doshi, M.D., director of Cardiac Electrophysiology and Pacing at Saint John's Health Center in Santa Monica, CA, and Saibal Kar, M.D., director of the Cardiovascular Intervention Center Research at Cedars-Sinai Hospital in Los Angeles, CA.
March 23, 2015
16:19 EDTBSXBoston Scientific leads funding round for InterVene
Subscribe for More Information
March 20, 2015
10:00 EDTBSXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:32 EDTBSXBoston Scientific has a conference call hosted by JPMorgan
JPMorgan Analyst Weinstein will host a conference call with CEO Mike Mahoney on March 27 at 11 am.
06:44 EDTBSXBoston Scientific initiated with an Outperform at Raymond James
Subscribe for More Information
March 18, 2015
05:39 EDTBSXSt. Jude Medical downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo downgraded St. Jude Medical (STJ) to Market Perform saying competitive pressures will drive 2015 market share losses in the company's cardiac rhythm management business, which represents 50% of total sales. Wells believes the launch of CardioMEMS will not be strong enough to offset the headwinds in CRM unit. The firm thinks Boston Scientific's (BSX) earlier than expected approval for its next generation subcutaneous implantable cardioverter-defibrillator called Emblem will drive share gains against St. Jude and Medtronic (MDT) in the single chamber ICD market. Wells cut its price target range for St. Jude shares to $69-$70 from $73-$74. The medical technology company closed yesterday down $2.01 to $65.45.
March 17, 2015
16:13 EDTBSXBoston Scientific announces FDA, CE Mark approval of EMBLEM S-ICD system
Boston Scientific has received FDA and CE Mark approval of the EMBLEM Subcutaneous Implantable Defibrillator, or S-ICD, system. The EMBLEM S-ICD System is a treatment option that provides protection for patients at risk of sudden cardiac arrest, yet leaves the heart and vasculature untouched, minimizing the risk of complications associated with conventional transvenous implantable cardioverter-defibrillators. A controlled and limited market release has begun in a small number of European centers with a broad European launch scheduled for May and subsequent U.S. launch planned for the third quarter of 2015.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use